Stonnington Group’s NovoCure NVCR Stock Holding History

Stonnington Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,920	Closed	-$560K	–	282
2021 Q2	$560K	Buy	+2,920	New	+$568K	0.12%	162

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonnington Group's NVCR Position: Q3 2021 in Review

Stonnington Group sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 2,920 shares — an estimated $560K sold.

Stonnington Group first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $560K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

Stonnington Group reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
Stonnington Group sold 2,920 NovoCure shares in Q3 2021, an estimated $560K.
Stonnington Group first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
Stonnington Group's NovoCure position peaked at $560K in Q2 2021.
317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Stonnington Group's 13F filing for Q3 2021, filed 12 Oct 2021.